


17512(HL)



IFW
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Xiao et al.)
)
Serial No.: 10/602,350)
Conf. No.: 7786)
Filed: Herewith)
)
For: Methods and Compositions)
for The Treatment of Cancer)
)
Examiner: Not yet assigned)

Group Art Unit: Not yet assigned

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Supplemental IDS-Non-Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date of Deposit: 5/24/2004
Person making Deposit: BONNIE FERGUSON
Signature: Bonnie Ferguson
Date of Signature: 5/24/2004

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

The references listed on the attached PTO-1449 form are being brought to the attention of the Examiner under 37 C.F.R. §1.97(c) for consideration in connection with the examination of the above-identified patent application. None of these publications are admitted to be prior art to the presently claimed invention, but are deemed of sufficient relevance to be brought to the attention of the Examiner.

Each item of information contained in this Supplemental Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

17512(HL)
Serial No. 10/602,350


PATENT

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO-1449 form with initials or other appropriate marks.


No fee is believed due in connection with this communication in accordance with 37 C.F.R. § 1.97(c) and 37 C.F.R. § 1.97(e). However, if Applicant is in error, please charge any fees that may be due in connection with this Information Disclosure Statement to Deposit Account No. 01-0885.

Respectfully submitted,

Date: 5/21/04



Carlos A. Fisher
Reg. No. 36,510
ALLERGAN, INC.
T2-7H
2525 Dupont Drive
Irvine, CA 92612
Tel: 714-246-4920
Fax: 714-246-4249



LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET: 17512(HL)	SERIAL NO.: 10/602,350
APPLICANT: Xiao et al	TITLE: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
FILING DATE: June 23, 2003	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

BA	Feng et al. Suprabasal expression of a dominant-negative RXR alpha mutant in transgenic mouse epidermis impairs regulation of gene transcription and basal keratinocyte proliferation by RAR-selective retinoids. Genes Dev. 1997, Vol. 11, pages 59-71
BB	Stewart et al, Retinoids differentially regulate the proliferation of colon cancer cells lines. Exp. Cell Res. 1997, Vol. 233, pages 321-329.
BC	Sheikh et al, Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids. J. Biol. Chem. 26 August 1994, Vol. 269, No. 34, pages 21440-21447.
BD	Sato et al, Expression of peroxisome proliferators-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of (PPAR) gamma agonists, Br. J. Cancer. 2000, Vol. 83, No. 10, pages 1394-140

EXAMINER _____ **DATE CONSIDERED** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.